|Center for Vaccine and Biomedical Research|
|HEAD||Dr SADORGE Christine / firstname.lastname@example.org|
|MEMBERS||Dr BARON Camille / BECHET Stéphane / JOLLY Nathalie
The centre is responsible for carrying out the sponsor duties for the development of vaccine candidates and for biomedical research initiated by researchers at the Institut. For vaccine development, it is part of an integrated organization including the Antiviral Immunity, Biotherapy and Vaccines Unit (M.-L. Gougeon) and the Cochin-Pasteur Clinical Research Centre (O. Launay).
Grants have been obtained allowing the centre to be involved in early clinical development (proof of concept) of various anti-infective vaccine candidates such as vaccines against HIV, anthrax, malaria and shigellosis. In addition, we prepared the early development plan of the Mag-tn3 (C. Leclerc), an anti-cancer immunotherapy for which the first clinical trial will be performed with Institut Curie.
Vaccine against Shigellosis
The estimated annual number of episodes of Shigella infection is 165 million, the majority being observed in developing countries and 70% of cases being children. The annual number of deaths is roughly 1 million, two third being children below 5 years of age.
SC599 Shigella vaccine phase I results
The SC599 is a live attenuated Shigella dysenteriae type-1 (SD1) icsA ent fep stxA:HgR oral vaccine developed by P. Sansonetti. This vaccine was first evaluated in 28 healthy adult volunteers at the Saint-George Vaccine Institute (SGVI) in London (D. Lewis). It was an inpatient, prospective, open labeled not placebo controlled study with sequential dose-escalating cohorts. All doses tested from 102 up to 108 Colony Forming Unit (CFU) included were well tolerated. An immune response was observed at doses of 105 CFU and higher. The immunogenicity was defined as the number of B lymphocytes producing IgM, IgG and IgA specific for SD1 lipopolysaccharides as measured by the Elispot technique (Paper under submission).
SC599 Shigella vaccine phase IIa (ongoing)
The phase I results provided the rationale for a comparative double-blind placebo-controlled study of two doses (105 and 107 CFU) of SC599 in healthy volunteers. The primary objective is to demonstrate the superiority in terms of immunogenicity of the two tested doses versus placebo. The secondary objective is to compare the clinical and biological tolerance and to explore the vaccine shedding. One hundred and eleven volunteers were enrolled (may-2005, sept-2006) in the study at the SGVI and at the Cochin-Pasteur CRC (Data analysis in 2007).
Biomedical research support
The centre was/is involved in various biomedical researches such as: Plasmodium falciparum transcriptome analysis during parasite in vitro development in erythrocytes from adult sickle-cell trait carriers (P. David) ; mechanisms of tumour immunity in patients with carcinoma of the bladder (M. Albert) ; inter-relationships of hepatitis viruses genotypes and/or variants with the environment and impact on liver cancer (P. Pineau) ; development of a high-performance technique for intravitam diagnosis of rabies in man (H. Bourhy) ; human immune response to Yersinia pestis (C. Demeure).
Members of the centre are involved within two courses of the Pasteur School of Infectiology: “Clinical trials for infectious and tropical diseases” and “Epidemiology and Biostatistics”.
|More informations on our web site|
|Publications 2006 of the unit on Pasteur's references database|
Activity Reports 2006 - Institut Pasteur
If you have problems with this Web page, please write to email@example.com